Adoptive immunotherapy based on donor leukocyte infusions (DLI) with or after allogeneic hematopoietic transplantation is a promising concept in the treatment of malignant 1,2 and infectious diseases. 3, 4 In addition, donor T lymphocytes significantly contribute to preventing graft rejection and to enhancing post-transplant immune competence. However, infusion of allogeneic T lymphocytes is frequently associated with an immune reaction against host tissue which may lead to a severe, potentially lethal graft-versus-host disease (GVHD).
Adoptive immunotherapy based on donor leukocyte infusions (DLI) with or after allogeneic hematopoietic transplantation is a promising concept in the treatment of malignant 1, 2 and infectious diseases. 3, 4 In addition, donor T lymphocytes significantly contribute to preventing graft rejection and to enhancing post-transplant immune competence. However, infusion of allogeneic T lymphocytes is frequently associated with an immune reaction against host tissue which may lead to a severe, potentially lethal graft-versus-host disease (GVHD). 5 Consequently, much effort has been made to separate the 'graft-versus-malignancy' effects, eg 'graft-versus-leukemia' (GVL), from GVH reactions. 5, 6 One concept relies on a gene therapy approach for the control of GVHD. 7, 8 This strategy is based on retroviral vector-mediated introduction of a so-called 'suicide gene' Herpes simplex virus thymidine kinase (HSVtk) into T cells allowing their in vivo elimination in the event of GVHD. The available clinical experience supports the conclusion that infusion of suicide gene-modified T cells is feasible. [8] [9] [10] Although the approach has been successful in several patients, impaired T cell function seems to be a major shortcoming. 10, 11 Other problems such as low retroviral gene transfer efficiencies into primary T lymphocytes and gen- eration of non-functional HSVtk transgenes have been successfully addressed in recent years. 12, 13 It has recently been shown that the conservation of T cell functions is strongly dependent on ex vivo culture conditions. Since oncoretroviral vectors require cell cycling for stable transgene insertion, activation of T lymphocytes, usually with OKT-3 (± anti-CD28) and IL-2, is an essential part of all current transduction protocols. 12 Type and duration of ex vivo culture, as well as the selection regimen for enrichment of transduced lymphocytes may strongly influence their functional capabilities. 11, [14] [15] [16] [17] Shortening of the ex vivo culture period and inclusion of optimized selection markers for enrichment of transgenic cells are consequently of high importance for the further development of adoptive immunotherapy with suicide gene-modified T lymphocytes. Moreover, cells have to be processed in compliance with good manufacturing practice (GMP), implying the need for clinically approved reagents during cell culture and selection.
We have recently introduced a new gene transfer marker, truncated human CD34 (tCD34), which may be of value for clinical use.
18 tCD34 is a naturally occurring splice variant of the human CD34 sialomucin that lacks the majority of the intracellular signal transduction domains. We now present data on novel retroviral vectors co-expressing tCD34 with a splice-corrected version of HSVtk 13 allowing for both rapid positive selection of gene-modified cells and their conditional elimination by ganciclovir (GCV) administration.
In order to ensure sufficient transgene expression in T Gene Therapy lymphocytes, new retroviral vectors have been developed based on MP71. 19, 20 These vectors combine the strong promotor of MPSV and the 5' untranslated region of MESV, in which viral gene remnants have been deleted, while generating an artificial intron (leader 71). In order to obtain sufficient co-expression of the two transgenes we cloned three different vectors using this backbone as shown in Figure 1a . In two vectors, the transgenes are linked via an internal ribosomal entry side (IRES) of the encephalomyocarditis virus (EMCV). 21 Either the authentic viral ATG (ATG 11) is utilized for translation initiation of the second gene (ie tCD34) with the ATG of tCD34 following 9 bp in frame (= vector R1) or the authentic viral ATG is replaced by the start codon of tCD34 (R2). The third vector (F) encodes a tCD34-HSVtk fusion protein. Integrity of all vectors was confirmed by sequence analysis (data not shown).
Next we generated gibbon ape leukemia virus envelope (GALVenv)-pseudotyped vector-containing supernatants for all three constructs in Phoenix gp producer cells. Therefore, a GALVenv expression plasmid was developed on the basis of a recently described expression construct for envelope glycoproteins. 22 The GALVenv vector was co-transfected with gagpol-and vector plasmids as previously described and supernatant was harvested at various time-points thereafter. 22, 23 After titration on human fibroblasts (~2 × 10 6 infectious particles/ml), we infected Jurkat and primary T cells at an MOI of about 1 as described. 24, 25 In some experiments, an analogous retroviral vector encoding enhanced green fluorescent protein (eGFP) 23 was used in parallel as a control.
Initial experiments with Jurkat cells demonstrated
Figure 1 Transduction of Jurkat cells with retroviral vectors encoding both tCD34 and scHSVtk using different co-expression strategies. (a) Identical retroviral vector backbones with an MPSV LTR and MESV leader 71 have been used to ensure sufficient transgene expression in T cells. (b) For transduction, infectious particles pseudotyped with the GALVenvelope protein were generated from Phoenix gp producer cells co-transfected with plasmids encoding the GALV env and the retroviral vector. 22 FACS analysis 18 of Jurkat cells transduced according to our established protocol 24 revealed different gene transfer efficiencies (shown as percentages of CD34-positive cells) and transgene expression levels (indicated as mean fluorescence (MF)). An EMCV-IRES vector mediating CD34 expression from the authentic viral codon (R1) allowed highest CD34 levels. (c) Only the fusion vector and R1 facilitated efficient enrichment of gene-modified cells by magnetic cell sorting (MACS).
18 CD34 expression as measured by flow cytometry ( Figure  1b) for all three vectors. However, in each experiment transduction with R1 resulted in much higher expression levels than with both F or R2. For cells transduced with the latter vector, no clear separation of gene modified from non-infected cells could be seen by flow cytometry in some experiments. The higher expression of tCD34 from the second position in an IRES vector as compared with the fusion protein is an unexpected finding, because lower expression of IRES-mediated as compared with LTR-driven expression has been reported. 26 The same difference in expression levels (R1 > F) was found for primary T lymphocytes, but not in myeloid cell lines such as K562. Notably, in primary T cells we observed with both vectors even higher expression levels of tCD34 than in Jurkat cells (Figure 2a) . This underlines the usefulness of the MP71 backbone for transgene expression in primary T cells. Northern blot analysis revealed two signals of similar intensity representing the spliced and unspliced transcripts for both vectors R1 and F (not shown), indicating correct RNA processing. 20 However, despite the use of identical promoters, higher transcription levels of R1 as compared with F were observed in Jurkat cells, but not in myeloid K562 cells (not shown). This probably was the basis for the much stronger tCD34 expression from R1 in T cells and may indicate an effect of the IRES sequence on vector transcription.
We then proceeded with magnetic cell sorting (MACS) to enrich gene-modified T cells. 18 Initial experiments with Jurkat cells clearly indicated that cells transduced with either R1 or F could be efficiently sorted using MACS with resulting purities higher than 95%. Mean recovery Figure 1) as described. 24 
Transduction resulted in high CD34 expression for both vectors (F, upper panel; R1, lower panel) as shown by FACS analysis. (b)
Gene-modified cells could be enriched to very high purity using magnetic cell sorting. 18 rates of CD34 + cells were better for vector F (41% ± 13%; n = 4) as compared with vector R1 (26% ± 9%; n = 6). In contrast, expression of tCD34 from R2 was obviously not high enough to ensure efficient enrichment of gene-modified cells (Figure 1c) . For each vector, experiments were repeated at least three times with almost identical results. Due to the higher transgene expression levels in primary T cells (see above), even better separation of gene-modified cells was achieved with purities usually exceeding 99% (Figure 2b ). As for Jurkat cells, recovery rates were higher (76% ± 12%; n = 4) for vector F than for R1 (66 ± 10%; n = 3).
Current clinical protocols for adoptive immunotherapy with suicide gene-modified T lymphocytes explore either the neomycin phosphotransferase gene and selection with G418, 10 or ⌬LNGFR and immunoaffinity-based selection procedures.
8 G418 selection requires long in vitro culture and may also directly impair T cell function. 11 Selection of gene-modified cells based on surface marker expression as reported for ⌬LNGFR reduces the time of ex vivo cell culture which results in better conservation of functional capabilities. 8, 11, 18 However, no clinically approved system for selection of ⌬LNGFR-modified cells is currently available. In contrast, tCD34 as a gene transfer marker allows enrichment of transduced T lymphocytes under clinical conditions with GMP-approved commercial devices. 18 We then examined whether enriched gene-modified cells could be efficiently eliminated by activating the suicide mechanism. Therefore, MACsorted cells were treated with two different concentrations (1 g/ml, 4 g/ml) of ganciclovir (GCV) reflecting therapeutic plasma levels in vivo. Application of GCV led to a rapid and strong suppression of cell growth in both Jurkat (see below) and primary T cells expressing the tCD34-HSVtk fusion protein: >99% of primary T lymphocytes were killed at 1 g/ml GCV, whereas eGFP-transduced cells were not Gene Therapy affected (Figure 3 ). Growth inhibition was much more efficient than in a historical control with a comparable vector 25 encoding truncated low-affinity nerve growth factor receptor (⌬LNGFR) as a selection marker. Using 1 g/ml GCV 95% ± 2% (n = 4) of tCD34-HSVtk-transduced Jurkat cells were killed as compared with 73% ± 10% (n = 9), whereas unspecific killing of non-transduced cells was in the same range in both experiments (5% ± 6% versus 6% ± 4%). 25 This difference may be due to lower expression of HSVtk in that vector, which incorporates an internal promoter. Moreover, a splice-corrected HSVtk version has been used in the current study. 13 Efficient action of a HSVtk fusion protein located at the cell membrane may be an unexpected finding. In a Western blot analysis of F-and R1-transduced Jurkat cells, we found all proteins to be of the expected size (not shown). Confocal microscopy ( Figure 4 ) using anti-CD34 monoclonal antibodies (Becton Dickinson) and anti-HSVtk antiserum (kindly provided by P Summers, Yale University) showed co-localization of tCD34 and scHSVtk at the cell membrane after transduction with the fusion gene vector, whereas no HSVtk was observed in the nucleus. These data are in agreement with previous work, where a neomycin resistance genes and HSVtk have successfully been fused indicating that HSVtk may well be active in the cytoplasm. 27 Degrève and colleagues 28 using an HSVtk/eGFP fusion construct identified a strong nuclear localization signal in HSVtk which targeted all protein to the nucleus. Deletion of this signal resulted in a cytoplasmic localization of the HSVtk/eGFP fusion protein without any loss of sensitivity of transfected cells to the growth inhibitory effects of antiherpes nucleoside analogues. 28, 29 These data taken together indicate that HSVtk may be active both in the nucleus and, as in our case, in the cytoplasm.
Interestingly, cells transduced with R1 and highly expressing tCD34 were only partially sensitive to GCV. In fact, only about 65% inhibition of R1-transduced Jurkat cells at 1 g/ml GCV and 80% at 4 g/ml GCV was observed after 1 week of treatment. Notably, most surviving cells still expressed tCD34 (not shown), but significant down-regulation of CD34 expression was observed even in the absence of GCV. These data indicate that very high expression of the IRES-driven second transgene, an unusual finding, may result in down-regulation of expression of the first transgene, HSVtk in the given case, or exert a direct toxic effect on the target cells. Indeed, down-regulation of IRES-driven tCD34 expression with R1 vectors was only seen in primary and cultivated T lymphocytes, which showed unusually high tCD34 levels, but not in K562 myeloid cells where initial tCD34 expression was moderate. Alternatively, a genetic instability of the R1 construct could be responsible. The underlying mechanism is currently under investigation. Altogether, the impaired sensitivity to GCV renders the IRES vector R1 unsuitable for suicide gene therapy, whereas the vector expressing the tCD34-scTK fusion protein shows promising features (high titer, sufficient expression of both selection markers).
Based on the above data we then established stable PG13-based producer clones using fluorescence activated cell sorting (FACS). Of 88 clones tested, nine clones with titers higher than 1 × 10 6 infectious particles were obtained. Currently the most suitable of these clones is processed under GMP conditions to generate a master cell bank and subsequent retroviral supernatant for clinical use. High-titer retroviral supernatant in conjunction with efficient gene transfer protocols 12, 30 will allow high transduction rates after just one infection cycle (at day 3 after initial stimulation). In combination with a selection method based on magnetic cell sorting, the whole procedure may, therefore, be shortened to 5 days. This would be an important improvement over existing protocols and vectors. Indeed, in an allogeneic transplantation model in rats, cultivation of T lymphocytes for a period longer than 6 days has been shown to be critical for their immunological potential. Only those T cells cultivated for 3-6 days were able to induce lethal GVHD at the same frequency as fresh T lymphocytes. 17 Safety of using tCD34 within an adoptive immunotherapy approach is a matter of discussion, because its role in vivo, in particular involvement in stem cell trafficking, is still under investigation. We have extensively studied possible side-effects of tCD34 expression in a mouse model. Retroviral expression of tCD34 in murine hematopoietic stem cells did not produce overt alterations of multilineage hematopoiesis in vivo in an observation period of 97 weeks after gene transfer and in three serial transplanations. 31 Importantly, T cells expressing tCD34 showed both normal levels and tissue distribution. Further studies have been initiated to explore the immunological capacity and safety of T cells modified with the fusion construct vector.
In conclusion, we have developed a vector for the manipulation of T cells which fuses a truncated CD34 for cell sorting and surface marking and a splice-corrected HSVtk as a suicide gene. We demonstrate that transduced T lymphocytes can be efficiently enriched using GMPcompatible, commercially available devices and retain sensitivity to GCV treatment. This would allow their specific elimination in the case of any side-effects conferred by these cells in vivo. We therefore suggest that our new sort-suicide vector may be of use within the concept of adoptive immunotherapy with suicide gene-modified allogeneic T lymphocytes.
